Medical 21

Executive Summary

Medical 21 is a San Diego-based medical device company developing the MAVERICS Graft, a synthetic, off-the-shelf regenerative graft for coronary artery bypass graft (CABG) surgery. Current CABG procedures require harvesting a patient's own vein or artery, leading to additional surgical trauma, donor-site complications, and prolonged recovery. Medical 21's innovative solution aims to eliminate the need for autologous grafts by providing a ready-to-use synthetic graft that promotes regeneration of native-like vascular tissue. This could significantly reduce operative time, post-operative pain, and complication rates, while enabling more consistent graft quality and availability. The MAVERICS Graft targets a large and growing market: over 400,000 CABG procedures are performed annually in the U.S. alone, and the global coronary bypass surgery market is valued at over $20 billion. With its unique bioengineered design, the graft has the potential to become a standard of care if clinical validation succeeds. Medical 21 has made progress in preclinical studies, demonstrating the graft's biocompatibility, mechanical integrity, and ability to support endothelialization. The company is now preparing for first-in-human clinical trials, which will be a critical milestone to prove safety and feasibility. Beyond clinical success, key challenges include scaling manufacturing, regulatory clearance (likely requiring a PMA from the FDA), and establishing a sales and distribution network. The company's intellectual property and proprietary technology position it well in the competitive landscape of vascular grafts. With a strong value proposition and favorable market dynamics, Medical 21 represents a promising investment opportunity in the cardiovascular medical device space, albeit at an early development stage.

Upcoming Catalysts (preview)

• Q1 2027Initiation of First-in-Human Clinical Trial70% success
• Q4 2026FDA Breakthrough Device Designation60% success
• Q2 2027Series B Financing Round50% success